113617-63-3 Orbifloxacin AKSci I546
Loading Please Wait...
  I546    AKSci Reference Standard
, 99% (HPLC)
1-Cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(cis-3,5-dimethyl-1-piperazinyl)-4-oxo-quinoline-3-carboxylic acid

CAS Number:113617-63-3
MDL Number:MFCD00864858
Purity:99% (HPLC)
Physical Form:Light yellow powder
Melting Point:259-265°C
Long-Term Storage:Store at room temperature


 Orbifloxacin (Orbax, Schering-Plough Animal Health) is a broad-spectrum fluoroquinolone antibiotic. Its mechanism of action is to inhibit bacterial DNA gyrase and prevent DNA supercoiling and synthesis.. The compound is approved for use in dogs for the treatment of urinary tract infections (cystitis) caused by susceptible strains of Staphylococcus pseudintermedius, Proteus mirabilis, Escherichia coli and Enterococcus faecalis. Orbifloxacin as an oral suspension is also indicated for skin and soft tissue infections in dogs caused by susceptible strains of Staphylococcus pseudintermedius, Staphylococcus aureus, coagulase positive staphylococci, Pasteurella multocida, Proteus mirabilis, Pseudomonas spp., Klebsiella pneumoniae, Escherichia coli, Enterobacter spp., Citrobacter spp., Enterococcus faecalis, β-hemolytic streptococci (Group G) and Streptococcus equisimilis.

[1]Matsumoto, Junichi; Miyamoto, Teruyuki; Egawa, Hiroshi; Nakamura, Shinichi Preparation of trifluoroquinolonecarboxylic acid derivatives as medical bactericides Eur. Pat. Appl. (1987), EP 242789 A2 19871028.
[2] Petersen, Uwe; Grohe, Klaus; Schriewer, Michael; Schenke, Thomas; Haller, Ingo; Metzger, Karl; Endermann, Rainer; Zeiler, Hans Joachim Preparation of 5-substituted quinolone- and naphthyridonecarboxylic acids as antibacterial agents Ger. Offen. (1988), DE 3711193 A1 19881013.
[3] Teruyuki Miyamoto , Junichi Matsumoto , Katsumi Chiba , Hiroshi Egawa , Kohichiro Shibamori , Akira Minamida , Yoshiro Nishimura , Hidetsugu Okada , Masahiro Kataoka Pyridonecarboxylic acids as antibacterial agents. Part 14. Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
[4] Gootz, Thomas D.; McGuirk, Paul R.; Moynihan, Melinda S.; Haskell, Suzanne L. Placement of alkyl substituents on the C-7 piperazine ring of fluoroquinolones: dramatic differential effects on mammalian topoisomerase II and DNA gyrase Antimicrobial Agents and Chemotherapy (1994), 38(1), 130-3.
[5] Nakamura S. Veterinary use of new quinolones in Japan. Drugs. 1995;49 Suppl 2:152-8.
[6] In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections.Gani?re JP, M?daille C, Etor? F. Res Vet Sci. 2004 Aug;77(1):67-71.
[7] Scott DW, Peters J, Miller WH JrEfficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs Scott DW, Peters J, Miller WH Jr. Can Vet J. 2006 Oct;47(10):999-1002.



Signal Word

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of October 19, 2019

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.

Download SDS

For research use only. Not for diagnostic or therapeutic use.
Not for human use.


 APIs and Bioactives > Antibacterials, Quinolones, Veterinary